Adverse effects of atypical antipsychotics: Differential risk and clinical implications

CNS Drugs

Volumn 21, Issue 11, 2007, Pages 911-936

  Haddad, Peter M ^a,b,c   Sharma, Sonu G ^a  

^a Cromwell House   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amisulpride, adverse reactions; Antipsychotics, adverse reactions; Aripiprazole, adverse reactions; Blood dyscrasias; Cerebrovascular disorders; Clozapine, adverse reactions; Drug withdrawal; Extrapyramidal disorders; Hyperglycaemia; Hyperprolactinaemia

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; AKATHISIA; BIPOLAR DISORDER; BLOOD DYSCRASIA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSLIPIDEMIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERPROLACTINEMIA; METABOLIC DISEASES; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 35048827065     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721110-00004     Document Type: Review

References (208)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60 (6): 553-64
2. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160 (7): 1209-22
3. Gaebel W, Weinmann S, Sartorius N, et al. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005; 187: 248-55
4. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67 (4): 509-16
5. Calabrese JR, Keck Jr PE, MacFadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162 (7): 1351-60
6. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162 (7): 1281-90
7. Murray CJ, Lopez AD. The global burden of disease: a compre hensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 projected to 2020. Cambridge (MA): Harvard School of Public Health, 1996
8. Haddad P, Dursun S, Deakin B, editors. Adverse syndromes and psychiatric drugs: a clinical guide. Oxford: Oxford University Press, 2004
9. Saltz BL, Woener MG, Kane JM, et al. A prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 66: 2402-6
10. Lin CH, Chen MC, Wang SY, et al. Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. J Formos Med Assoc 2004; 103 (6): 437-41
11. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
12. Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992; 19 (9): 603-6
13. Kerwin RW. The new atypical antipsychotics: a lack of extra-pyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry 1998; 164: 141-8
14. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. 53rd ed. London: BMJ Publishing Group Ltd and RPS Publishing, 2007 Mar
15. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators: effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23
16. Mann RD. Prescription-event monitoring: recent progress and future horizons. Br J Clin Pharmacol 1998; 46 (3): 195-201
17. Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin 2005; 21 (4): 565-70
18. Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry 2007; 191: S64-70
19. Ahmer S, Arya P, Anderson D, et al. Conflict of interest in psychiatry. Psychiatr Bull 2005; 29: 302-4
20. Casey DE. Neuroleptic induced extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, editor. Schizophrenia. Oxford: Blackwell, 1995: 546-55
21. Barnes TRE, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13 Suppl. 3: S49-57
22. Buhrich N, Weller A, Kevans P. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatr Serv 2000; 51 (7): 928-9
23. Prior TI, Baker GB. Anticholinergic toxicity. In: Haddad P, Dursun S, Deakin B, editors. Adverse syndromes and psychiatric drugs. Oxford: Oxford University Press, 2004: 293-7
24. Ashton H. Benzodiazepine dependence. In: Haddad P, Dursun S, Deakin B, editors. Adverse syndromes and psychiatric drugs. Oxford: Oxford University Press, 2004: 239-59
25. Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs: an update. Drug Saf 1993; 9 (4): 272-9
26. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321 (7273): 1371-6
27. Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003; 7 (13): 1-193
28. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUt-LASS 1). Arch Gen Psychiatry 2006; 63 (10): 1079-87
29. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361 (9369): 1581-9
30. National Institute for Clinical Excellence. Core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline 1. London: National Institute for Clinical Excellence, 2002 Dec
31. Song F. Risperidone in the treatment of schizophrenia: a meta analysis of randomised controlled trials. J Psychopharmocol 1997; 11: 65-71
32. Marder SR, Miebach RC. Risperidone in the treatment of schizophrenia. Am J Psych 1994; 151: 825-35
33. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
34. Freeman HL. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia. Int Clin Psychopharmacol 1997; 12 Suppl. 2: S11-17
35. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2006 Apr 19; (2): CD005237
36. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psych 2002; 14 (1): 47-57
37. Aravantis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of seroquel in patients with acute exacerbations of schizophrenia: a comparison with haloperidol and placebo. Biol Psych 1997; 42: 233-46
38. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in shortterm, placebo-controlled trials. Schizophr Res 2003; 61 (2-3): 123-36
39. Cooper SJ, Tweed J, Raniwalla J, et al. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 2000; 101 (3): 218-25
40. Friedman JH. Atypical antipsychotics in the EPS vulnerable patient. Psychoneuroendocrinology 2003; 28 Suppl. 1: 39-51
41. Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia a task force report of the American Psychiatric Association. Arlington (VA): American Psychiatric Association, 1992
42. Glazer WM, Morgenstern H, Doucette JT. Predicting the long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry 1993; 54: 133-9
43. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry 1999; 60 Suppl. 5: 43-7, discussion 48-9
44. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583-609
45. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155 (11): 1521-8
46. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double blind comparison of the incidence of tardive dyskinea in patients in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br J Psych 1999; 175: 391-2
47. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. Risperidone-USA-79 Study Group. N Engl J Med 2002; 346 (1): 16-22
48. Kane JM, Woerner M, Weinhold P, et al. Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacol Bull 1984; 20: 39-40
49. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of one year studies. Am J Psych 2004; 161 (3): 414-25
50. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 15: 1142-5
51. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1998; 248: 209-11
52. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 58: 503-10
53. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58: 318-22
54. Kinon BJ, Jeste DV, Kollack-Walker S, et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 985-96
55. Emsley R, Turner HJ, Schronen J, et al. A single-blind randomised trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004; 65: 696-701
56. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1342-8
57. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994; 35 (11): 886-7
58. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am J Psychiatry 1999; 156 (5): 796-7
59. Buzan RD. Risperidone-induced tardive dyskinesia. Am J Psychiatry 1996; 153 (5): 734-5
60. Herran A, Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine [letter]. Ann Intern Med 1999; 131 (1): 72
61. Casey DE. Spontaneous tardive dyskinesia; clinical and laboratory studies. J Clin Psychiatry 1985; 46: 42-7
62. Lieberman J, Kane J, Woerner M. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984; 20 (1): 22-6
63. Chakos MH, Alvir JMJ, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode schizophrenia. Arch Gen Psychiatry 1996; 53: 313-9
64. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157 (7): 1150-5
65. Tollefson GD, Birkett MA, Kiesler GM, et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Lilly Resistant Schizophrenia Study Group. Biol Psychiatry 2001; 49 (1): 52-63
66. Goodnick PJ, Jerry JM. Aripiprazole; profile on efficacy and safety. Expert Opin Pharmacother 2003; 3: 1773-81
67. Meltzer HY, Goode DJ, Schyve PM, et al. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979; 136: 1550-5
68. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549-57
69. Crawford AM, Beasley Jr CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26: 41-54
70. Jacobson J. Prolactin elevation with ziprasidone [letter]. Am J Psychiatry 2004; 161 (10): 1925
71. Otani K, Kondo T, Kaneko S, et al. Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. Int Clin Psychopharmacol 1994; 9 (4): 287-9
72. Peuskens J. Risperidone in the treatment of patients with chronic: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
73. Gruender G, Wetzel H, Schloesser R, et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 1999; 45: 89-97
74. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64 (20): 2291-314
75. Zelaschi NM, Delucchi GA, Rodriguez JL. High plasma prolactin levels after long-term neuroleptic treatment. Biol Psychiatry 1996; 39: 900-1
76. Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003; 64 (11): 1362-9
77. Haddad PM, Hellewell JSE, Wieck A. Antipsychotic-induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol 2001; 15: 293-5
78. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007; 190: 129-34
79. Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147-54
80. Hellewell JSE. Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy [abstract]. Eur Neuropsychopharmacol 1998; 8 Suppl.: S248
81. Wallace M. Real progress: the patient's perspective. Int Clin Psychopharmacol 2001; 16 Suppl.: S21-4
82. Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004; 19 (7): 415-22
83. Peuskens J, Sienaert P, De Heft M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry 1998; 13 Suppl. 1: S23-30
84. Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004; 24 (1): 56-61
85. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170 (8): 463-7
86. Wirshing DA, Pierre JM, Marder SR, et al. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002; 56 (1-2): 25-30
87. Mitchell J, Popkin M. The pathophysiology of sexual dysfunction associated with antipsychotic drug therapy in males: a review. Arch Sexual Behav 1983; 12: 173-83
88. Baldwin DS, Birtwistle J. Schizophrenia, antipsychotic drugs and sexual function. Prim Care Psychiatry 1997; 3: 115-23
89. Keitner GI, Selub S. Spontaneous ejaculations and neuroleptics. J Clin Psychopharmacol 1993; 3: 34-6
90. Patel AG, Mukherji K, Lee A. Priapism associated with psychotropic drugs. Br J Hosp Med 1996; 55: 315-9
91. Compton MT, Saldivia A, Berry SA. Recurrent priapism during treatment with clozapine and olanzapine [letter]. Am J Psychiatry 2000; 157: 659
92. Rosen SI, Hanno PM. Clozapine-induced priapism. J Urol 1992; 148: 876-7
93. Emes CE, Millson RC. Risperidone-induced priapism. Can J Psychiatry 1994; 39: 315-6
94. Deirmenjian JH, Erhart SM, Wirshing DA, et al. Olanzapine-induced reversible priapism: a case report. J Clin Psychopharmacology 1998; 18: 351-3
95. Songer DA, Barclay JC. Olanzapine-induced priapism. Am J Psychiatry 2001; 158: 2087-8
96. Pais VM, Ayvazian PJ. Priapism from quetiapine overdose: first report and proposal of mechanism [abstract]. Urology 2001; 58: 462
97. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002; 181: 49-55
98. Dickson RA, Glazer WM. Hyperprolactinaemia and male sexual dysfunction [letter]. J Clin Psychiatry 1999; 60: 125
99. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63: 408-13
100. Hummer M, Kemmler G, Kurz M, et al. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999; 156 (4): 631-3
101. Aizenberg D, Modai I, Landa A, et al. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 2001; 62: 541-4
102. Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29 (2): 125-47
103. Coulouvrat C, Dodney-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14: 209-18
104. Baldwin DS, Mayers AG, Lambert A. Sexual dysfunction. In: Haddad P, Dursun S, Deakin B, editors. Adverse syndromes and psychiatric drugs: a clinical guide. Oxford: Oxford University Press, 2004: 125-44
105. Angermeyer MC, Matschinger H. Attitude of family to neuroleptics. Psychiatr Prax 1999; 26: 171-4
106. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001; 16 (3): 153-62
107. Seidell JC. Societal and personal costs of obesity. Exp Clin Endocrinol Diabetes 1998; 106 Suppl. 2: 7-9
108. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1998; 282: 1523-9
109. Allison DB, Mentore JL, Heo M, et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96
110. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatrica Scand 2000; 101: 416-32
111. Haddad PM. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005; 19 (6 Suppl.): 17-27
112. Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153: 817-9
113. Briffa D, Meehan T. Weight changes during clozapine treatment. Aust N Z J Psychiatry 1998; 32: 718-21
114. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975-81
115. Novick D, Haro JM, Suarez D, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study [poster]. CINP Congress; 2006 Jul 9-13; Chicago (IL)
116. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Clin Psychiatry 2001; 62 (2): 92-100
117. Guansekara NS, Spencer CM. Quetiapine: a review of its use in schizophrenia. CNS Drugs 1998; 9: 325-40
118. Brecher M, Rak I, Melvin K, et al. The long term effects of quetiapine (Seroquel™) monotherapy on weight gain in patients with schizophrenia. Int J Psychiatry Clin Prac 2000; 4: 287-91
119. Pendlebury J, Haddad P, Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3-year results. Hum Psychopharmacol 2005; 20 (6): 447-8
120. Bushe C, Haddad P, Peveler R, et al. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005; 19 (6 Suppl.): 28-35
121. Hiles BW. Hyperglycemia and glucosuria following chlorpromazine therapy [letter]. JAMA 1956; 162: 1651
122. Cooperberg AA, Eidlow S. Haemolytic anaemia, jaundice and diabetes mellitus following chlorpromazine therapy. J Can Med Assoc 1956; 75: 746-9
123. Haddad PM. Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry Suppl 2004; 47: S80-6
124. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001; 111: 716-23
125. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-52
126. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23: 735-44
127. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004; 65 (6): 857-63
128. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27 (2): 596-601
129. Expert group. 'Schizophrenia and diabetes 2003' expert consensus meeting, Dublin 3-4 October 2003: consensus summary. Br J Psychiatry Suppl 2004; 47: S112-4
130. Lambert TJ, Chapman LH, Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-8
131. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59 (4): 337-45
132. Howes OD, Bhatnagar A, Gaughran FP, et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004; 161 (2): 361-3
133. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-9
134. Cohn TA, Wolever T, Bois D, et al. First epsiode and neuroleptic free patients with schziophrenia have reduced insulin sensitivity: a minimal model analysis [abstract]. Schizophren Bull 2005; 31: 197-8
135. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184: 58-62
136. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004; 65 (10): 1335-42
137. Taylor D, Young C, Mohamed R, et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005; 19 (2): 182-6
138. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003; 48 (5): 345-7
139. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006; 164 (7): 672-81
140. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-6
141. Lieberman JA, Philips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-epsiode schizophrenia: a 52-week randomised trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003
142. Gough S, Peveler R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatry 2004; 184 Suppl. 47: S106-11
143. Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107 (17): 2185-9
144. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther 1970; 11 (6): 883-9
145. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64 (7): 701-23
146. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65 Suppl. 18: 47-56
147. Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007; 68 (3): 406-9
148. Bushe C, Paton C. The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol 2005; 19 (6 Suppl.): 76-83
149. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70 (1): 1-17
150. Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacology 2004; 24 Suppl. 1: S1-6
151. Expert Consensus Meeting. Metabolic and lifestyle issues and severe mental illness: new connections to well-being? J Psychopharmacol 2005; 19 (6 Suppl.): 118-22
152. Physicians' desk reference. 55th ed. Montvale (NJ): Medical Economics Company Inc, 2001
153. Reinert RE, Hermann CG. Unexplained deaths during chlorpromazine therapy. J Nerv Ment Dis 1960; 131: 435-42
154. Ban TA, St Jean A. Electrocardiographic changes induced by phenothiazine drugs. Am Heart J 1965; 70: 575-6
155. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62 (11): 1649-71
156. Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal (CPMP/986/96) [online]. Available from URL: http://www.coresearch.biz/regulations/cpmp.pdf [Accessed 2007 Aug 22]
157. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2005; (3): CD001715
158. Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole and clozapine. J Clin Psychopharmacol 2001; 21: 8-13
159. US FDA, Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (ziprasidone hydrochloride), 19 July, 2000 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf [Accessed 2007 Sep 25]
160. Committee on Safety of Medicines and the Medicines Control Agency. Clozapine and cardiac safety: updated advice for prescribers. Curr Probl Pharmacovigilance 2002; 28: 8
161. Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841-5
162. Warner B, Alphs L, Schadelin J, et al. Clozapine and sudden death. Lancet 2000; 355: 842-3
163. Hagg S, Spigset O, Soderstrohm TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155-6
164. Henderson DC, Daley TB, Kunkel L, et al. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004; 65 (5): 686-9
165. Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (7): 1125-43
166. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006; 88 (1-3): 63-72
167. Chengappa KN, Pollock BG, Parepally H, et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 2000; 20 (3): 311-6
168. Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother 2000; 34 (5): 662-5
169. Levin TT, Barrett J, Mendelowitz A. Death from clozapine-induced constipation: case report and literature review. Psychosomatics 2002; 43 (1): 71-3
170. John JP, Chengappa KN, Baker RW, et al. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995; 7 (3): 119-25
171. Laker MK, Cookson JC. Reflux oesophagitis and clozapine. Int Clin Psychopharmacology 1997; 12: 37-9
172. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576-80
173. Clozaril® summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 1277 [Accessed 2007 Sept 11]
174. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146 (7): 486-92
175. Silverstone PH. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J Clin Psychopharmacol 1998; 18 (1): 86-8
176. Blier P, Slater S, Measham T, et al. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharma-col 1998; 13 (3): 137-40
177. Hollister LE, Eikenberry DT, Raffel S. Chlorpromazine in non-psychotic patients with pulmonary tuberculosis. Am Rev Resp Dis 1960; 81: 562-3
178. Tranter R, Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol 1996; 12: 401-6
179. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24 (3): 183-97
180. Simpson GM, Varga E. Clozapine: a new antipsychotic agent. Curr Ther Res 1974; 16: 679-86
181. Borison RL, Diamond BI, Sinha D, et al. Clozapine withdrawal rebound psychosis. Psychopharmacology Bull 1998; 24: 260-3
182. Eklund K. Supersensitivity and clozapine withdrawal [letter]. Psychopharmacology 1987; 91: 135
183. Ahmed S, Chengappa KN, Naidu VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998; 59 (9): 472-7
184. Poyurovsky M, Bergman Y, Shoshani D, et al. Emergence of obsessive-compulsive symptoms and tics during clozapine withdrawal. Clin Neuropharmacol 1998; 21: 97-100
185. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
186. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77: 185-202
187. Farver DK. Neroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003; 2: 21-35
188. Heyland D, Sauve M. Neuroleptic malignant syndrome without the use of neuroleptics. CMAJ 1991; 145 (7): 817-9
189. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (4): 464-70
190. Bottlender R, Jager M, Hofschuster E, et al. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry 2002; 35 (3): 119-21
191. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004; 19 (6): 351-3
192. Keck PE, Pope HG. Declining frequency of neroleptic malignant syndrome. Am J Psych 1991; 148: 880-2
193. Kane JM. Factors which can make patients difficult to treat. Br J Psych Suppl 1996; 31: 10-4
194. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 out patients with schizophrenia. Am J Psych 1996; 153: 417-9
195. Marks RC, Luchins DJ. Antipsychotic medications and seizures. Psychiatr Med 1991; 9 (1): 37-52
196. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003; 39 (7): 551-7
197. Devinsky O, Honigfeld G, Patin J. Clozapine related seizures. Neurology 1991; 41: 369-71
198. Zoleptil: summary of product characteristics. Newbury; Orion Pharma (UK) Ltd, 2002
199. Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines (CEM/CMO/200401) [online]. Available from URL: http://www.info.doh.gov.uk/doh/embroadcast.nsf/
200. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294 (15): 1934-43
201. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14 (3): 191-210
202. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355 (15): 1525-38
203. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445-8
204. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5
205. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353 (22): 2335-41
206. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66 (9): 1090-6
207. Chue P. The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol 2006; 20 (6 Suppl.): 38-56
208. Chaplin R, Lelliott P, Quirk A, et al. Negotiating styles adopted by consultant psychiatrists when prescribing antipsychotics. Adv Psychiatr Treat 2007; 13: 43-50